CD8A and breast cancer: Furthermore, in a spontaneous in vivo model of breast cancer, cancer cells stimulate systemic inflammation by producing IL-1β, which leads to stimulation of IL-17 production by γδT cells [57] and can inhibit anti-tumor CD8+ T cell activity [57].